Influence of moxifloxacin, comparator drugs and some fractions of pulmonary surfactant on adherence of some respiratory pathogens.
BACKGROUND
This study evaluated the effect of moxifloxacin and comparator drugs with or without some fractions of pulmonary surfactant, as surfactant protein-A (SP-A) and phospholipids, on the adherence of the most common respiratory pathogens.


METHODS
The adherence of respiratory pathogens to a bronchial epithelial cell line was tested. Antimicrobials were used at 1/2, 1/4 and 1/8 minimum inhibitory concentration (MIC), SP-A at 1 and 5 microg/ml and phospholipids at 50 microg/ml.


RESULTS
At 1/2 MIC moxifloxacin, ciprofloxacin, amoxicillin-clavulanate and ceftriaxone reduced the adherence of Staphylococcus aureus and Streptococcus pneumoniae to values of 40-50%. At the same concentration, cotrimoxazole reduced the adherence values of Moraxella catarrhalis and Haemophilus influenzae to about 50%, while beta-lactams showed high efficacy only on H. influenzae, with adherence values of about 40%. The addition of SP-A and/or phospholipids to the tested antibiotics had no effect on bacterial adherence.


CONCLUSIONS
The non-interference of SP-A and/or phospholipids with the suppressive effect that some antibiotics exert on bacterial adherence could represent a favorable event during antibiotic therapy.
Ferrara
A
A
Dos Santos
C
C
Tellarini
M T
MT
D000900:Anti-Bacterial Agents / Q000494:pharmacology; D000890:Anti-Infective Agents / Q000494:pharmacology*; D001372:Aza Compounds; D002448:Cell Adhesion / Q000187:drug effects*; D002460:Cell Line; D004347:Drug Interactions; D004847:Epithelial Cells / Q000187:drug effects / Q000502:physiology; D024841:Fluoroquinolones; D006193:Haemophilus influenzae / Q000187:drug effects / Q000502:physiology; D006801:Humans; D008168:Lung / Q000166:cytology; D001936:Moraxella catarrhalis / Q000187:drug effects / Q000502:physiology; D000077266:Moxifloxacin; D010743:Phospholipids / Q000494:pharmacology; D037662:Pulmonary Surfactant-Associated Protein A / Q000494:pharmacology*; D011663:Pulmonary Surfactants / Q000494:pharmacology*; D011804:Quinolines; D013211:Staphylococcus aureus / Q000187:drug effects / Q000502:physiology; D013296:Streptococcus pneumoniae / Q000187:drug effects / Q000502:physiology
D000900:Anti-Bacterial Agents; D000890:Anti-Infective Agents; D001372:Aza Compounds; D024841:Fluoroquinolones; D010743:Phospholipids; D037662:Pulmonary Surfactant-Associated Protein A; D011663:Pulmonary Surfactants; D011804:Quinolines; D000077266:Moxifloxacin